An interventional study of Neuromodulation Rehabilitation in Multiple Sclerosis, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-07-09.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment
The investigators hypothesis is that electrical stimulation to the tongue that directly stimulates two cranial nerve nuclei (Trigeminal and Facial Nerve Nuclei), will excite neural impulses to the brainstem and cerebellum. The investigators call this cranial nerve non-invasive neuromodulation (CN-NINM). The activation of these structures induces neuroplasticity when combined with specific physical exercises, can reduce symptoms of advanced MS, targeting primarily postural stability (sitting and standing), upper extremity movement, and ability to perform self-transfers.
The intervention will be similar to that used in the investigators previous work with movement disorders, and will be tailored to the address issues unique to individuals with advanced MS.
The study will enroll a total of 6 subjects having advanced MS that present with significant seated and standing balance, posture, or movement control deficits due to MS.
Subjects will complete twice-daily lab training for two weeks (5 days/week). Each lab training (morning and afternoon) includes 1.5 to 2 hours of instruction in balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training.
Activities are performed in 20-minute sessions with concomitant electrical stimulation of the tongue. The intervention is customized according to each subject's particular symptoms and tolerance. If a subject is not able to perform this amount of training, the training will be adapted to a level that is tolerable.
After these 2 weeks, subjects will continue to perform these same intervention activities at home for 4 weeks. They will return to the lab for 1 week of training and testing, then perform home training for 4 weeks. This cycle is repeated for a total of 5 cycles.
After the 6 months have been completed, subjects may choose to participate in an optional second phase of the study. The second phase includes an additional 12 months of participation in which subjects perform the intervention activities at home training and return to the lab on time per month for 2 hours of testing and 2 hours of training.
If successful, this study would indicate that CN-NINM intervention may reduce the symptoms of advanced MS.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 6 is below the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →University of Wisconsin, Madison is the lead sponsor of 1,161 studies on the registry; 182 are open to participants now.
Of its 151 completed or terminated interventional studies of FDA-regulated products, 114 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects will have a score between 6.5 to 7.5 on the Kurtzke Expanded Disability Status Scale (EDSS). The EDSS is a method of quantifying disability in people with multiple sclerosis.
Subjects will have reached a plateau in an MS focused physical rehabilitation program in the 6 months prior to enrollment.
Exclusion Criteria:
Subjects will have no major co-morbidities, especially neurological disorders, uncontrolled pain, hypertension or diabetes. All subjects, if on medications, will not have had any major changes in type or dosage in within 3 months of enrollment. Additionally, candidates will be excluded if they:
Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
Device: Neuromodulation Rehabilitation
CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Also known as: Cranial Nerve Non-invasive Neuromodulation (CN-NINM), Portable Neuromodulation Stimulator (PoNS)
Trunk Impairment Scale (TIS)
Static and dynamic sitting balance and trunk coordination are evaluated by a clinician. It is scored on a scale from 0-23, where the higher the score, the more improved the balance. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, and 21 weeks
Static Standing Balance Test
Clinician measures standing balance for up to 30 seconds in each of 5 conditions: feet 10 cm apart, feet together, stride stance, tandem stance, and single leg stance with eyes open and eyes closed. Total score is the sum of all 5 conditions. Higher scores indicate better balance. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Impact of Visual Impairment Scale (IVIS)
A 5-item self-report questionnaire that assesses the extent to which various activities dependent upon vision are affected by MS-related visual problems. Scores range from 0-15, with higher scores indicating a greater impact of visual problems on daily activities. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, and 21 weeks
Medical Outcomes Study (MOS) Pain Effects Scale (PES)
A self-report scale that assesses the ways in which pain and unpleasant sensation interfere with mood, ability to walk or move, sleep, work, recreation, and enjoyment of life. This assessment is used for subjects who have pain. Scores can range from 6-30. Items are scaled so that higher scores indicate a greater impact of pain on a patient's mood and behavior. Symptom specific test, only used for participants who presented symptom. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, and 21 weeks
Bladder Control Scale (BLCS)
A 4-item self-report scale to evaluate the impact of bladder control on lifestyle. This assessment is used for subjects with bladder issues. Scores can range from 0-22, with higher scores indicating greater bladder control problems. Symptom specific test, only used for participants who presented symptom. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Bowel Control Scale (BWCS)
A 5-item self-report scale to evaluate the impact of bowel control on lifestyle. This assessment is used for subjects with bowel issues. Scores can range from 0-26, with higher scores indicating greater bowel control problems. Symptom specific test, only used for participants who presented symptom. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
A brief, clinician-administered test that helps determine the neuropsychological status of adults who have neurologic injury or disease such as dementia, head injury, and stroke. This tool consists of a battery of tests. Raw scores are transformed to a 0-120 scale, with a higher score indicating higher function. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Walking Distance
Clinician measures how far the individual can walk until fatigue requires him/her to stop. Longer distances demonstrate improvement. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Walking Speed
Assessed by timing the first 25 feet that the person walked. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
12-item MS Walking Scale (MSWS-12)
A 12-item self-report measure of the impact of MS on a person's walking. Raw scores are transformed to a 0-100 scale. A reduction in score indicates improvement. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Box & Blocks (B&B) Assessment - Right
A standardized clinical assessment of gross upper limb dexterity. Subjects move small blocks from one side of a box to the other within a time period (one minute). Each side is tested separately. The score is the number of blocks moved from 0-150. A higher score indicates improvement. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Box & Blocks (B&B) Assessment - Left
A standardized clinical assessment of gross upper limb dexterity. Subjects move small blocks from one side of a box to the other within a time period (one minute). Each side is tested separately. The score is the number of blocks moved from 0-150. A higher score indicates improvement. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Multiple Sclerosis Impact Scale (MSIS-29) - Physical
A 29-item self-report tool that measures the impact of MS on day-to-day life. There are 3 scores, physical, psychological, and total score. Raw scores are transformed to a 0-100 scale. A higher score indicates a greater impact of disease on daily function. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Multiple Sclerosis Impact Scale (MSIS-29) - Psychological
A 29-item self-report tool that measures the impact of MS on day-to-day life. There are 3 scores, physical, psychological, and total score. Raw scores are transformed to a 0-100 scale. A higher score indicates a greater impact of disease on daily function. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Modified Fatigue Impact Scale (MFIS)
A self-report tool that assesses the perceived impact of fatigue on daily activities. Consists of 21 items selected from the Fatigue Impact Scale. Scored on a 0-84 scale. A higher score indicates a greater impact of fatigue on daily activities. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Gross Motor Function Measure (GMFM)
The GMFM a standardized observational instrument that measures change in gross motor function. Subscales include lying \& rolling; sitting; crawling \& kneeling; standing; and walking, running \& jumping. For the complete test, the raw scores are converted to a 0-100 scale, with higher scores indicating greater functional mobility. The items that we used were scored on a 0-3 scale and changes reported in percent improvement. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 6, 11, 16, 21 and 27 weeks
Slump Test
Measures and quantifies changes in trunk control during functional sitting. It was quickly determined that this test duplicated the TIS and was difficult to score objectively so the decision was made not to use it for the study. Performance-based and tested in participants who possessed the ability to perform the assessment.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Modified Rivermead Mobility Index
An 8 item assessment that quantifies the ability to perform transfers. It has been validated in persons with stroke and a mixed neurologic population (43% MS). Score is a 0-40 scale. A higher score indicates higher function. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
Video Nystagmography (VNG)
VNG is a standardized eye tracking test used to measure static and dynamic eye movement control to detect oculomotor abnormalities typically associated with degenerative neurological disorders, particularly in the brainstem and cerebellum. The subject wears goggles while an infrared video camera monitors and records eye movement as the eyes follow a dot on a computer screen.
Time frame: Change from Baseline at 2, 6, 11, 16, 21 and 27 weeks
| Milestone | Neuromodulation Rehabilitation |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Static and dynamic sitting balance and trunk coordination are evaluated by a clinician. It is scored on a scale from 0-23, where the higher the score, the more improved the balance. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.82 |
| Baseline to Week 6 | 2.58 |
| Baseline to Week 11 | 1.47 |
| Baseline to Week 16 | 1.63 |
| Baseline to Week 21 | 3.06 |
Clinician measures standing balance for up to 30 seconds in each of 5 conditions: feet 10 cm apart, feet together, stride stance, tandem stance, and single leg stance with eyes open and eyes closed. Total score is the sum of all 5 conditions. Higher scores indicate better balance. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.90 |
| Baseline to Week 6 | 0.57 |
| Baseline to Week 11 | 1.04 |
| Baseline to Week 16 | 0.90 |
| Baseline to Week 21 | 0.49 |
| Baseline to Week 27 | 0.32 |
A 5-item self-report questionnaire that assesses the extent to which various activities dependent upon vision are affected by MS-related visual problems. Scores range from 0-15, with higher scores indicating a greater impact of visual problems on daily activities. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 1.27 |
| Baseline to Week 6 | 2.12 |
| Baseline to Week 11 | 3.54 |
| Baseline to Week 16 | 3.54 |
| Baseline to Week 21 | 2.12 |
A self-report scale that assesses the ways in which pain and unpleasant sensation interfere with mood, ability to walk or move, sleep, work, recreation, and enjoyment of life. This assessment is used for subjects who have pain. Scores can range from 6-30. Items are scaled so that higher scores indicate a greater impact of pain on a patient's mood and behavior. Symptom specific test, only used for participants who presented symptom. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.55 |
| Baseline to Week 6 | 0.64 |
| Baseline to Week 11 | 0.71 |
| Baseline to Week 16 | 0.40 |
| Baseline to Week 21 | 1.00 |
A 4-item self-report scale to evaluate the impact of bladder control on lifestyle. This assessment is used for subjects with bladder issues. Scores can range from 0-22, with higher scores indicating greater bladder control problems. Symptom specific test, only used for participants who presented symptom. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.30 |
| Baseline to Week 6 | 0.30 |
| Baseline to Week 11 | 0.13 |
| Baseline to Week 16 | 0.41 |
| Baseline to Week 21 | 0.62 |
| Baseline to Week 27 | 0.27 |
A 5-item self-report scale to evaluate the impact of bowel control on lifestyle. This assessment is used for subjects with bowel issues. Scores can range from 0-26, with higher scores indicating greater bowel control problems. Symptom specific test, only used for participants who presented symptom. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 1.20 |
| Baseline to Week 6 | 0.68 |
| Baseline to Week 11 | 0.52 |
| Baseline to Week 16 | 1.04 |
| Baseline to Week 21 | 0.86 |
| Baseline to Week 27 | 0.35 |
A brief, clinician-administered test that helps determine the neuropsychological status of adults who have neurologic injury or disease such as dementia, head injury, and stroke. This tool consists of a battery of tests. Raw scores are transformed to a 0-120 scale, with a higher score indicating higher function. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | -0.12 |
| Baseline to Week 6 | 0.39 |
| Baseline to Week 11 | 0.24 |
| Baseline to Week 16 | 0.78 |
| Baseline to Week 21 | 1.94 |
| Baseline to Week 27 | 0.51 |
Clinician measures how far the individual can walk until fatigue requires him/her to stop. Longer distances demonstrate improvement. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.89 |
| Baseline to Week 6 | 0.75 |
| Baseline to Week 11 | 0.76 |
| Baseline to Week 16 | 0.69 |
| Baseline to Week 21 | 0.67 |
| Baseline to Week 27 | 0.26 |
Assessed by timing the first 25 feet that the person walked. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.77 |
| Baseline to Week 6 | 0.84 |
| Baseline to Week 11 | 1.00 |
| Baseline to Week 16 | 1.01 |
| Baseline to Week 21 | -0.41 |
| Baseline to Week 27 | -0.94 |
A 12-item self-report measure of the impact of MS on a person's walking. Raw scores are transformed to a 0-100 scale. A reduction in score indicates improvement. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | -0.50 |
| Baseline to Week 6 | 0.43 |
| Baseline to Week 11 | 0.87 |
| Baseline to Week 16 | 0.50 |
| Baseline to Week 21 | 1.33 |
| Baseline to Week 27 | -0.42 |
A standardized clinical assessment of gross upper limb dexterity. Subjects move small blocks from one side of a box to the other within a time period (one minute). Each side is tested separately. The score is the number of blocks moved from 0-150. A higher score indicates improvement. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.52 |
| Baseline to Week 6 | 0.45 |
| Baseline to Week 11 | 0.47 |
| Baseline to Week 16 | 1.17 |
| Baseline to Week 21 | 0.21 |
| Baseline to Week 27 | 4.95 |
A standardized clinical assessment of gross upper limb dexterity. Subjects move small blocks from one side of a box to the other within a time period (one minute). Each side is tested separately. The score is the number of blocks moved from 0-150. A higher score indicates improvement. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.07 |
| Baseline to Week 6 | 0.50 |
| Baseline to Week 11 | 0.80 |
| Baseline to Week 16 | 0.58 |
| Baseline to Week 21 | -0.04 |
| Baseline to Week 27 | 0.00 |
A 29-item self-report tool that measures the impact of MS on day-to-day life. There are 3 scores, physical, psychological, and total score. Raw scores are transformed to a 0-100 scale. A higher score indicates a greater impact of disease on daily function. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 1.58 |
| Baseline to Week 6 | 0.61 |
| Baseline to Week 11 | 0.94 |
| Baseline to Week 16 | 0.89 |
| Baseline to Week 21 | 1.46 |
| Baseline to Week 27 | -0.71 |
A 29-item self-report tool that measures the impact of MS on day-to-day life. There are 3 scores, physical, psychological, and total score. Raw scores are transformed to a 0-100 scale. A higher score indicates a greater impact of disease on daily function. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 1.77 |
| Baseline to Week 6 | 1.17 |
| Baseline to Week 11 | 0.86 |
| Baseline to Week 16 | 0.98 |
| Baseline to Week 21 | 2.05 |
| Baseline to Week 27 | 0.35 |
A self-report tool that assesses the perceived impact of fatigue on daily activities. Consists of 21 items selected from the Fatigue Impact Scale. Scored on a 0-84 scale. A higher score indicates a greater impact of fatigue on daily activities. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 0.87 |
| Baseline to Week 6 | 3.10 |
| Baseline to Week 11 | 2.54 |
| Baseline to Week 16 | 1.75 |
| Baseline to Week 21 | 1.40 |
| Baseline to Week 27 | 0.20 |
The GMFM a standardized observational instrument that measures change in gross motor function. Subscales include lying \& rolling; sitting; crawling \& kneeling; standing; and walking, running \& jumping. For the complete test, the raw scores are converted to a 0-100 scale, with higher scores indicating greater functional mobility. The items that we used were scored on a 0-3 scale and changes reported in percent improvement. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 6 | 0.82 |
| Baseline to Week 11 | 1.10 |
| Baseline to Week 16 | 1.19 |
| Baseline to Week 21 | 0.84 |
| Baseline to Week 27 | 0.16 |
Measures and quantifies changes in trunk control during functional sitting. It was quickly determined that this test duplicated the TIS and was difficult to score objectively so the decision was made not to use it for the study. Performance-based and tested in participants who possessed the ability to perform the assessment.
No measurements were reported for this outcome.
An 8 item assessment that quantifies the ability to perform transfers. It has been validated in persons with stroke and a mixed neurologic population (43% MS). Score is a 0-40 scale. A higher score indicates higher function. Performance-based and tested in participants who possessed the ability to perform the assessment. Effect size is reported (quantified difference between baseline and time point). The larger the absolute value, the stronger the effect. Cohen's guidelines for social sciences indicate 0.10 as a "small" effect size, 0.30 as a "medium" effect size, and 0.50 as a "large" effect size.
| percentage of change | Neuromodulation Rehabilitation |
|---|---|
| Baseline to Week 2 | 1.01 |
| Baseline to Week 6 | 1.21 |
| Baseline to Week 11 | 0.94 |
| Baseline to Week 16 | 1.44 |
| Baseline to Week 21 | 1.15 |
| Baseline to Week 27 | 0.38 |
VNG is a standardized eye tracking test used to measure static and dynamic eye movement control to detect oculomotor abnormalities typically associated with degenerative neurological disorders, particularly in the brainstem and cerebellum. The subject wears goggles while an infrared video camera monitors and records eye movement as the eyes follow a dot on a computer screen.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neuromodulation Rehabilitation | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Neuromodulation Rehabilitation |
|---|---|
| Viral InfectionInfections and infestations | 2/6 |
| InjuryInjury, poisoning and procedural complications | 1/6 |
| Trigeminal Neuralgia (TN)Nervous system disorders | 1/6 |
| FatigueGeneral disorders | 1/6 |
| Osteoarthritis PainMusculoskeletal and connective tissue disorders | 1/6 |
| Age, Categorical(Participants) | Neuromodulation Rehabilitation |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 5 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Neuromodulation Rehabilitation |
|---|---|
| Female | 5 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | Neuromodulation Rehabilitation |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Neuromodulation Rehabilitation |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Neuromodulation Rehabilitation |
|---|---|
| United States | 6 |
| Disease Chronicity(years) | Neuromodulation Rehabilitation |
|---|---|
| Mean | 17.7 ± 7.4 |
| EDSS Score(units on a scale) | Neuromodulation Rehabilitation |
|---|---|
| Mean | 7.0 ± 0.4 |
| MS Subtype(participants) | Neuromodulation Rehabilitation |
|---|---|
| SPMS | 5 |
| PPMS | 1 |
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison